Results 91 to 100 of about 605,792 (294)

The pituitary TGFb1 system as a novel target for the treatment of resistant prolactinomas [PDF]

, 2016
Prolactinomas are the most frequently observed pituitary adenomas and most of themrespond well to conventional treatment with dopamine agonists (DAs).
Camilletti, María Andrea, Diaz, Graciela Susana, Recouvreux, Maria Victoria, Rifkin, Daniel B.   +3 more
core   +2 more sources

Clinical Implications of Ki‐67 Index, Grade and Hormonal Changes in Pancreatic Neuroendocrine Tumors: Insights Into Tumor Heterogeneity Based on Primary and Secondary Lesions

Journal of Hepato-Biliary-Pancreatic Sciences, EarlyView.
ABSTRACT Background Pancreatic neuroendocrine tumors (PanNETs) show heterogeneity, including temporal shifts in proliferation and hormone production; however, their clinical implications remain uncertain. Methods This retrospective study included 114 patients with metastatic or recurrent PanNETs at Kyushu University Hospital.
Masatoshi Murakami, Nao Fujimori, Kazuhide Matsumoto, Keijiro Ueda, Kohei Nakata, Masafumi Nakamura, Takeo Yamamoto, Yoshinao Oda, Tetsuhide Ito, Yoshihiro Ogawa   +9 more
wiley   +1 more source

Somatostatin receptors in gastroentero-pancreatic neuroendocrine tumours [PDF]

, 2003
Five somatostatin receptor (sst) subtype genes, sst(1), sst(2), sst(3), sst(4) and sst(5), have been cloned and characterised. The five sst subtypes all bind natural somatostatin-14 and somatostatin-28 with high affinity.
Herder, W.W. (Wouter) de, Hofland, L.J. (Leo), Lamberts, S.W.J. (Steven), Lely, A-J. (Aart-Jan) van der   +3 more
core   +2 more sources

Molecular theranostics: principles, challenges and controversies

Journal of Medical Radiation Sciences, Volume 72, Issue 1, Page 156-164, March 2025.
Molecular theranostics offers a powerful tool to drive precision medicine in nuclear oncology. While theranostics is not a new principle in nuclear medicine, recent advances in instrumentation and radiopharmacy have driven a reinvigoration and a broader suite of applications.
Geoffrey Currie
wiley   +1 more source

AIP and MEN1 mutations and AIP immunohistochemistry in pituitary adenomas in a tertiary referral center. [PDF]

, 2019
Background: Pituitary adenomas have a high disease burden due to tumor growth/ invasion and disordered hormonal secretion. Germline mutations in genes such as MEN1 and AIP are associated with early onset of aggressive pituitary adenomas that can be ...
Cano González, David A., Flores Martínez, Álvaro, Venegas Moreno, Eva   +2 more
core  

Combined biological therapy with lanreotide autogel and cabergoline in the treatment of MEN-1-related insulinomas. [PDF]

, 2014
Multiple endocrine neoplasia type 1 (MEN1) is a hereditary syndrome associated with the development of many endocrine tumors, involving mainly pituitary, parathyroids, pancreas, although a proliferative state interests all neuroendocrine system.
Camera, L, Carratù, A, Colao, A, de Luca di Roseto, C, Del Prete, M, Di Somma, C, Faggiano, A., Marciello, F, Marotta, V, Ramundo, V   +9 more
core   +1 more source

Metastatic Malignant Paraganglioma Presenting as a Neck Mass Treated with Radiolabeled Somatostatin Analog [PDF]

, 2021
Waqas Jehangir, Alexander Karabachev, Jackie Tsao, Christopher J. Anker, Sree Susmitha Garapati, Janusz Kikut, Hibba tul Rehman   +6 more
openalex   +1 more source

PERCC1‐associated enteropathy: Diagnostic challenges and enteral autonomy achieved with teduglutide

JPGN Reports, EarlyView.
Abstract Congenital diarrheas and enteropathies (CODE) are rare inherited disorders characterized by early‐onset intractable diarrhea. Though progress has been made in elucidating the genetic basis of CODE, much remains to be discovered. Another challenge is the lack of curative therapies—treatment is primarily supportive including enteral and ...
Angela Tran, Vivien Nguyen, Phuong Huynh
wiley   +1 more source

A review of the use of somatostatin analogs in oncology

OncoTargets and Therapy, 2013
Somatostatin is a neuropeptide produced by paracrine cells that are located throughout the gastrointestinal tract, lung, and pancreas, and is also found in various locations of the nervous system.
O. Keskin, Ş. Yalçın
semanticscholar   +1 more source

Advances in the treatment of gastroenteropancreatic neuroendocrine tumors

Clinical and Experimental Gastroenterology, 2010
Pamela L Kunz, George A FisherStanford University Medical Center, CA, USAAbstract: Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are a rare and heterogeneous class of neoplasms.
Pamela L Kunz, George A Fisher
doaj